Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
The company claims that its Empagliflozin tablets are the most affordable in India
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
Since its inception, the company has either acquired or taken a majority stake in five companies
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
The company plans to expand its portfolio in regulated markets aggressively
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug
Subscribe To Our Newsletter & Stay Updated
